Polygenic risk scores for prostate cancer: testing considerations.

Toland, Amanda Ewart

Toland, Amanda Ewart.

Afiliação

Toland AE; Department of Cancer Biology and Genetics and Division of Human Genetics, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.

Can J Urol ; 26(5 Suppl 2): 17-18, 2019 Oct.

Article em En | MEDLINE | ID: mdl-31629419

ABSTRACT

ABSTRACT

Genome-wide association studies (GWAS) have identified more than 170 single nucleotide variants (SNVs) associated with prostate cancer risk. Each variant is associated with only small increases in risk and is not predictive of an individuals' overall risk of developing prostate cancer. Polygenic risk scores (PRS) combining these variants are now clinically available and may improve predictive value of other factors such as PSA. This overview reviews the current state of PRS for prostate cancer including testing considerations.

Assuntos

Testes Genéticos; Herança Multifatorial; Neoplasias da Próstata/diagnóstico; Neoplasias da Próstata/genética; Humanos; Masculino; Neoplasias da Próstata/epidemiologia; Medição de Risco

Buscar no Google

Imprimir

XML

PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Testes Genéticos / Herança Multifatorial Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Buscar no Google

Imprimir

XML

PubMed Links